Hansa Medical CEO Arvidson Dies
Executive Summary
Hansa Medical announces the sudden death of its CEO Göran Arvidson.
You may also be interested in...
Hansa Medical's 'Game Changer' In Transplantations May Have Other Uses Too
Hansa Medical AB, a Swedish-listed, clinical-stage biotech, is focused on developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases that could change the face of kidney transplants.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.